

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d)  
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 29, 2026**

**ENCISION, INC.**

(Exact name of registrant as specified in its charter)

**Colorado**  
(State or other jurisdiction of incorporation)

**001-11789**  
(Commission File Number)

**84-1162056**  
(I.R.S. Employer Identification No.)

**6797 Winchester Circle, Boulder, Colorado**  
(Address of principal executive offices)

**80301**  
(Zip Code)

**(303) 444-2600**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
<b>Common Stock, no par value</b>	<b>ECIA</b>	<b>OTC Bulletin Board</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.02 Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.**

**Item 8.01. Other Events**

On January 29, 2026, Encision Inc. (the “Company”) announced that it plans to deregister its common stock and suspend its reporting obligations with the Securities and Exchange Commission. The Company’s deregistration will be effective ninety (90) days after the date of the filing of the Form 15, expected to be filed on or about January 29, 2026.

A copy of the press release announcing the Company’s intent to deregister is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

99.1 [Press Release dated January 29, 2026](#)

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ENCISION, INC.**

(Registrant)

Date: January 29, 2026

/s/ Robert Fries

Robert Fries

Interim CEO

Principal Executive Officer



For Immediate Release

## Encision Inc. Announces Decision to Deregister its Common Stock

Boulder, Colorado, January 29, 2026 -- Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced today that its Board of Directors approved the filing of a Form 15 with the Securities and Exchange Commission ("SEC") to voluntarily deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934 ("the Exchange Act").

The Company intends to file the Form 15 on or about January 29, 2026. As a result of the filing of the Form 15, the Company's reporting obligations, including its obligations to file annual and quarterly reports on Forms 10-K, 10-Q and 8-K with the SEC, will be suspended. Other filing requirements will terminate upon the effective date of the Form 15, which is expected to occur 90 days after filing.

Encision's CEO Robert Fries commented, "The Company's decision to deregister was made after careful consideration of the advantages and disadvantages, and considering our size and market capitalization, and the high costs and demands on management's time of our ongoing compliance with SEC and Sarbanes-Oxley reporting requirements. We expect to recognize considerable cost savings associated with this decision."

Encision intends to continue to prepare and publish unaudited quarterly and annual financial results.

The Company also expects that the Company's common stock will continue to be traded in the over-the-counter market under the ticker symbol "ECIA". No guarantee, however, can be made that a trading market in the Company's common stock through any over-the-counter market will be maintained.

Encision designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.

---

### Forward-looking Statements:

Discussions of some of the matters contained in this press release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and, as such, may involve risks and uncertainties.